Get started
Rigel Pharmaceuticals, Inc.Rigel Pharmaceuticals, Inc.Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

RIGL chart


Full chart

RIGL upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪390.00 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
100.69
Basic EPS (TTM)
0.22 USD
Net income (FY)
‪−25.09 M‬ USD
Revenue (FY)
‪116.88 M‬ USD
Shares float
‪17.27 M‬
Beta (1Y)
3.36

Employees


Employees (FY)
147
Change (1Y)
−8 −5.16%
Revenue / Employee (1Y)
‪795.12 K‬ USD
Net income / Employee (1Y)
‪−170.69 K‬ USD

About Rigel Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Raul R. Rodriguez
Headquarters
South San Francisco
Website
rigel.com
Founded
1996
FIGI
BBG000BPWTW7
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RIGL news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RIGL is 22.14 USD — it has increased by 1.51% in the past 24 hours. Watch Rigel Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Rigel Pharmaceuticals, Inc. stocks are traded under the ticker RIGL.
RIGL stock has risen by 23.00% compared to the previous week, the month change is a 31.63% rise, over the last year Rigel Pharmaceuticals, Inc. has showed a 72.97% increase.
We've gathered analysts' opinions on Rigel Pharmaceuticals, Inc. future price: according to them, RIGL price has a max estimate of 57.00 USD and a min estimate of 14.00 USD. Watch RIGL chart and read a more detailed Rigel Pharmaceuticals, Inc. stock forecast: see what analysts think of Rigel Pharmaceuticals, Inc. and suggest that you do with its stocks.
RIGL reached its all-time high on Jan 3, 2001 with the price of 1,147.50 USD, and its all-time low was 6.40 USD and was reached on Jun 13, 2022. View more price dynamics on RIGL chart.
See other stocks reaching their highest and lowest prices.
RIGL stock is 5.96% volatile and has beta coefficient of 3.36. Track Rigel Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Rigel Pharmaceuticals, Inc. there?
Today Rigel Pharmaceuticals, Inc. has the market capitalization of ‪390.00 M‬, it has increased by 0.12% over the last week.
Yes, you can track Rigel Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Rigel Pharmaceuticals, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
RIGL earnings for the last quarter are 0.70 USD per share, whereas the estimation was 0.06 USD resulting in a ‪1.10 K‬% surprise. The estimated earnings for the next quarter are 0.45 USD per share. See more details about Rigel Pharmaceuticals, Inc. earnings.
Rigel Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪55.31 M‬ USD, despite the estimated figure of ‪41.94 M‬ USD. In the next quarter, revenue is expected to reach ‪50.10 M‬ USD.
RIGL net income for the last quarter is ‪12.42 M‬ USD, while the quarter before that showed ‪−1.03 M‬ USD of net income which accounts for ‪1.31 K‬% change. Track more Rigel Pharmaceuticals, Inc. financial stats to get the full picture.
No, RIGL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 24, 2025, the company has 147.00 employees. See our rating of the largest employees — is Rigel Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Rigel Pharmaceuticals, Inc. EBITDA is ‪11.42 M‬ USD, and current EBITDA margin is −16.47%. See more stats in Rigel Pharmaceuticals, Inc. financial statements.
Like other stocks, RIGL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Rigel Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Rigel Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Rigel Pharmaceuticals, Inc. stock shows the buy signal. See more of Rigel Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.